SG11201809693SA - SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS - Google Patents
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERSInfo
- Publication number
- SG11201809693SA SG11201809693SA SG11201809693SA SG11201809693SA SG11201809693SA SG 11201809693S A SG11201809693S A SG 11201809693SA SG 11201809693S A SG11201809693S A SG 11201809693SA SG 11201809693S A SG11201809693S A SG 11201809693SA SG 11201809693S A SG11201809693S A SG 11201809693SA
- Authority
- SG
- Singapore
- Prior art keywords
- substituted imidazo
- international
- compounds
- co7d
- pyridazines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332151P | 2016-05-05 | 2016-05-05 | |
PCT/US2017/031189 WO2017192930A1 (en) | 2016-05-05 | 2017-05-05 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809693SA true SG11201809693SA (en) | 2018-11-29 |
Family
ID=60203606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809693SA SG11201809693SA (en) | 2016-05-05 | 2017-05-05 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
Country Status (12)
Country | Link |
---|---|
US (3) | US11168087B2 (zh) |
EP (1) | EP3452481A4 (zh) |
JP (1) | JP7164774B2 (zh) |
KR (1) | KR102530515B1 (zh) |
CN (1) | CN109311902B (zh) |
AU (1) | AU2017261291C1 (zh) |
BR (1) | BR112018072552A8 (zh) |
CA (1) | CA3022670A1 (zh) |
IL (1) | IL262698B (zh) |
MX (1) | MX2018013529A (zh) |
SG (1) | SG11201809693SA (zh) |
WO (1) | WO2017192930A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6734860B2 (ja) | 2014-11-06 | 2020-08-05 | リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. | 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用 |
ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
EP3440083A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
AU2017246455B2 (en) | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
SG11201809693SA (en) | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
KR102662197B1 (ko) | 2017-10-30 | 2024-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노이미다조피리다진 |
EP3747885A4 (en) | 2018-01-31 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC CONNECTION |
CN108299382A (zh) * | 2018-03-14 | 2018-07-20 | 常州沃腾化工科技有限公司 | 一种盐酸阿替卡因中间体的制备方法 |
CA3114722A1 (en) * | 2018-10-01 | 2020-04-09 | Genzyme Corporation | Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use |
CN115160220A (zh) * | 2022-08-06 | 2022-10-11 | 上海泰坦科技股份有限公司 | 一种吡啶-n-氧化物的合成工艺 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ[1,2−a]−1,3,5−トリアジン−4−オン系化合物 |
US20020048610A1 (en) | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
JP4070966B2 (ja) | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
BR0213026A (pt) | 2001-10-22 | 2004-10-05 | Pfizer | Compostos de imidazopiridina como reguladores do receptor 5-ht4 |
WO2003074525A1 (fr) * | 2002-03-01 | 2003-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Compose heterocyclique azote |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
WO2004026868A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
CA2523077A1 (en) | 2003-04-21 | 2004-11-04 | Pfizer Inc. | Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity |
BRPI0416217A8 (pt) | 2003-11-12 | 2018-05-08 | Amicus Therapeutics Inc | composto derivado de hidroxipiperidina, métodos para a síntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamífero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir beta-glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexível curto |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
JPWO2005077953A1 (ja) * | 2004-02-18 | 2007-10-18 | 萬有製薬株式会社 | 含窒素縮合ヘテロ芳香環誘導体 |
DE602005007215D1 (de) | 2004-05-14 | 2008-07-10 | Cleveland Clinic Foundation | Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter |
MXPA06014809A (es) | 2004-06-21 | 2007-02-12 | Hoffmann La Roche | Derivados de pirazol-pirimidina. |
WO2006015737A1 (de) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
US7956061B2 (en) | 2005-01-19 | 2011-06-07 | Merck Sharp & Dohme Corp. | Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
BRPI0607927A2 (pt) | 2005-02-11 | 2009-10-20 | Hoffmann La Roche | derivados de pirazol-pirimidina |
DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
CN101203483A (zh) | 2005-04-21 | 2008-06-18 | 大日本住友制药株式会社 | N-取代的苯乙酰胺衍生物和包含该衍生物的药物组合物 |
JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
WO2007048065A2 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
WO2007065664A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
US7829579B2 (en) | 2006-06-23 | 2010-11-09 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
WO2008019363A2 (en) | 2006-08-07 | 2008-02-14 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5ht3 modulators |
EP2102211A2 (en) | 2006-11-20 | 2009-09-23 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2008063670A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
EP2137187A1 (en) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
EA201000003A1 (ru) | 2007-06-21 | 2010-06-30 | Айрм Ллк | Ингибиторы протеинкиназ и способы их применения |
WO2009060835A1 (ja) | 2007-11-05 | 2009-05-14 | Kyoto University | 新規ユビキリン結合性小分子 |
EP2217601A1 (en) * | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
JP2011504931A (ja) | 2007-11-28 | 2011-02-17 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としての2−フルオロピラゾロ[1,5−a]ピリミジン |
US8389527B2 (en) | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
US20110118236A1 (en) | 2008-03-25 | 2011-05-19 | Michiyo Mochizuki | Heterocyclic compound |
MX2010012010A (es) | 2008-05-01 | 2010-11-30 | Sirtris Pharmaceuticals Inc | Quinolinas y analogos relacionados como moduladores de sirtuin. |
KR101676886B1 (ko) | 2008-10-14 | 2016-11-16 | 엔타시스 테라퓨틱스 리미티드 | 박테리아 감염의 치료를 위한 융합된 스피로시클릭 헤테로방향족 화합물 |
CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
IN2012DN01961A (zh) * | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
ES2912284T3 (es) | 2010-12-08 | 2022-05-25 | Us Health | Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
EP2688872A4 (en) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
EP2723384B1 (en) | 2011-06-22 | 2018-08-29 | The General Hospital Corporation | Treatment of proteinopathies |
KR101778354B1 (ko) | 2011-08-18 | 2017-09-13 | 니뽄 신야쿠 가부시키가이샤 | 헤테로환 유도체 및 의약 |
CA2847075A1 (en) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Substituted annellated pyrimidine and the use thereof |
WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
KR20140077963A (ko) * | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
MX2014007731A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
SG11201405563VA (en) | 2012-03-09 | 2014-10-30 | Lexicon Pharmaceuticals Inc | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
CN104220071A (zh) | 2012-03-09 | 2014-12-17 | 莱西肯医药有限公司 | 抑制转接物关联激酶1以治疗疼痛 |
JP2015512913A (ja) | 2012-03-28 | 2015-04-30 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 |
RU2014149684A (ru) | 2012-05-31 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Производные аминохиназолина и пиридопиримидина |
EP2865671B1 (en) | 2012-06-22 | 2017-11-01 | Sumitomo Chemical Company, Ltd | Fused heterocyclic compound |
WO2014025651A1 (en) | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
CA2883574A1 (en) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
WO2014075168A1 (en) | 2012-11-16 | 2014-05-22 | University Health Network | Pyrazolopyrimidine compounds |
US9938258B2 (en) | 2012-11-29 | 2018-04-10 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
CA2892608C (en) | 2012-12-07 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
KR20140086002A (ko) | 2012-12-28 | 2014-07-08 | 한미약품 주식회사 | Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체 |
US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
WO2015012328A1 (ja) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | 複素環化合物 |
EP3035921A1 (en) | 2013-08-20 | 2016-06-29 | Bristol-Myers Squibb Company | Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia |
TW201605866A (zh) * | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 |
TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
DK3122726T3 (en) | 2014-03-27 | 2018-10-08 | Acad Medisch Ct | N- (5 - ((Aryl or heteroaryl) methyloxy) pentyl) -substituted imino sugars as inhibitors of glucosylceramide synthase |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
JP6734860B2 (ja) * | 2014-11-06 | 2020-08-05 | リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. | 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用 |
ES2958391T3 (es) * | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
EP3317282B1 (en) | 2015-07-01 | 2020-12-09 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
EP3344632A4 (en) | 2015-09-04 | 2019-03-20 | Lysosomal Therapeutics Inc. | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
KR20180081584A (ko) * | 2015-11-18 | 2018-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
EP3440083A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
AU2017246455B2 (en) | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
WO2017192841A1 (en) | 2016-05-04 | 2017-11-09 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
SG11201809693SA (en) * | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
EP3452480A4 (en) | 2016-05-05 | 2019-11-06 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
WO2019126776A1 (en) | 2017-12-21 | 2019-06-27 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
-
2017
- 2017-05-05 SG SG11201809693SA patent/SG11201809693SA/en unknown
- 2017-05-05 AU AU2017261291A patent/AU2017261291C1/en active Active
- 2017-05-05 CN CN201780037953.7A patent/CN109311902B/zh active Active
- 2017-05-05 US US16/097,905 patent/US11168087B2/en active Active
- 2017-05-05 EP EP17793402.3A patent/EP3452481A4/en active Pending
- 2017-05-05 WO PCT/US2017/031189 patent/WO2017192930A1/en unknown
- 2017-05-05 JP JP2018557821A patent/JP7164774B2/ja active Active
- 2017-05-05 BR BR112018072552A patent/BR112018072552A8/pt active Search and Examination
- 2017-05-05 KR KR1020187035087A patent/KR102530515B1/ko active IP Right Grant
- 2017-05-05 CA CA3022670A patent/CA3022670A1/en active Pending
- 2017-05-05 MX MX2018013529A patent/MX2018013529A/es unknown
- 2017-08-16 US US15/678,468 patent/US9868742B2/en active Active
-
2018
- 2018-10-31 IL IL262698A patent/IL262698B/en unknown
-
2021
- 2021-07-26 US US17/385,269 patent/US11878979B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2018142052A3 (zh) | 2020-09-28 |
CN109311902B (zh) | 2022-07-15 |
US11878979B2 (en) | 2024-01-23 |
EP3452481A4 (en) | 2020-02-26 |
KR102530515B1 (ko) | 2023-05-09 |
RU2018142052A (ru) | 2020-06-05 |
BR112018072552A2 (pt) | 2019-02-19 |
IL262698A (en) | 2018-12-31 |
US20170355702A1 (en) | 2017-12-14 |
AU2017261291A1 (en) | 2018-11-22 |
WO2017192930A1 (en) | 2017-11-09 |
JP7164774B2 (ja) | 2022-11-02 |
KR20190003738A (ko) | 2019-01-09 |
IL262698B (en) | 2022-04-01 |
MX2018013529A (es) | 2019-07-04 |
AU2017261291B2 (en) | 2021-11-18 |
BR112018072552A8 (pt) | 2023-03-14 |
AU2017261291C1 (en) | 2022-05-26 |
CA3022670A1 (en) | 2017-11-09 |
US9868742B2 (en) | 2018-01-16 |
US20220185814A1 (en) | 2022-06-16 |
EP3452481A1 (en) | 2019-03-13 |
CN109311902A (zh) | 2019-02-05 |
JP2019514956A (ja) | 2019-06-06 |
US11168087B2 (en) | 2021-11-09 |
US20190389866A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809693SA (en) | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804934PA (en) | Novel Compounds | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy |